Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

Excerpt

The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer, written by Ramesh K. Ramanathan, Daniel D. Von Hoff, Ferry Eskens, George Blumenschein Jr., Donald Richards, Isabelle Genvresse, Susanne Reschke, Camille Granvil, Adam Skubala, Carol Peña & Klaus Mross, was originally published Online First without Open Access. After publication in volume 15, issue 2, pages 163–174 the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2020 and the article is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://​creativecommons.​org/​licenses/​by-nc/​4.​0/​. …